KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EBT: 2010-2025

Historic EBT for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to $9.5 million.

  • Pacira BioSciences' EBT rose 106.86% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.8 million, marking a year-over-year increase of 176.17%. This contributed to the annual value of -$63.1 million for FY2024, which is 202.28% down from last year.
  • Pacira BioSciences' EBT amounted to $9.5 million in Q3 2025, which was up 594.24% from -$1.9 million recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' EBT peaked at $37.9 million during Q2 2023, and registered a low of -$138.9 million during Q3 2024.
  • Moreover, its 3-year median value for EBT was $13.6 million (2024), whereas its average is $1.4 million.
  • In the last 5 years, Pacira BioSciences' EBT skyrocketed by 702.37% in 2023 and then slumped by 936.43% in 2024.
  • Pacira BioSciences' EBT (Quarterly) stood at -$6.2 million in 2021, then plummeted by 191.51% to -$18.1 million in 2022, then soared by 286.63% to $33.7 million in 2023, then fell by 24.30% to $25.5 million in 2024, then surged by 106.86% to $9.5 million in 2025.
  • Its EBT was $9.5 million in Q3 2025, compared to -$1.9 million in Q2 2025 and $8.7 million in Q1 2025.